Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Reata Pharma
(NQ:
RETA
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Sep 25, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Reata Pharma
< Previous
1
2
3
4
5
6
Next >
Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Shareholder Notice: Investigation over Potential Wrongdoing
October 04, 2023
San Diego, CA -- (SBWIRE) -- 10/04/2023 -- An investigation was announced over potential breaches of fiduciary duties by certain directors at Reata Pharmaceuticals, Inc.
Via
SBWire
Biogen Completes Acquisition of Reata Pharmaceuticals
September 26, 2023
From
Biogen Inc.
Via
GlobeNewswire
Reata Pharmaceuticals Inc. (NASDAQ: RETA) Climbs to New 52-Week High
September 21, 2023
Via
Investor Brand Network
Reata Pharmaceuticals Stockholders Approve Merger Transaction With Biogen Inc.
September 21, 2023
From
Reata Pharmaceuticals, Inc.
Via
Business Wire
Reata Pharmaceuticals Inc. (NASDAQ: RETA) is a Stock Spotlight on 7/17
July 17, 2023
Via
Investor Brand Network
Reata Pharmaceuticals Inc. (NASDAQ: RETA) is a Stock Spotlight on 5/5
May 05, 2023
Via
Investor Brand Network
REATA PHARMACEUTICALS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Reata Pharmaceuticals, Inc. - RETA
August 28, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Earthstone Energy, Inc. (NYSE - ESTE), Fiesta Restaurant Group, Inc. (Nasdaq - FRGI), Veritiv Corporation (NYSE - VRTV), Reata Pharmaceuticals, Inc. (Nasdaq - RETA)
August 21, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fiesta Restaurant Group, Inc. (Nasdaq - FRGI), Veritiv Corporation (NYSE - VRTV), New Relic, Inc. (NYSE - NEWR), Reata Pharmaceuticals, Inc. (Nasdaq - RETA)
August 17, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: EchoStar Corporation (Nasdaq - SATS), Sovos Brands, Inc. (Nasdaq - SOVO), Reata Pharmaceuticals, Inc. (Nasdaq - RETA), Amedisys, Inc. (Nasdaq – AMED)
August 08, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fiesta Restaurant Group, Inc. (Nasdaq - FRGI), Veritiv Corporation (NYSE - VRTV), New Relic, Inc. (NYSE - NEWR), Reata Pharmaceuticals, Inc. (Nasdaq - RETA)
August 07, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
REATA PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Reata Pharmaceuticals, Inc. - RETA
August 02, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: New Relic, Inc. (NYSE - NEWR), Reata Pharmaceuticals, Inc. (Nasdaq - RETA), Talaris Therapeutics, Inc. (Nasdaq - TALS), Inpixon® (Nasdaq - INPX)
August 01, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Reata Pharmaceuticals, Inc. (Nasdaq – RETA), Talaris Therapeutics, Inc. (Nasdaq – TALS), Inpixon® (Nasdaq – INPX), Amedisys, Inc. (Nasdaq – AMED)
July 28, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
Biogen (NASDAQ: BIIB) Acquires Reata (NASDAQ: RETA) to Boost its Neurological Therapeutics Portfolio, Including SKYCLARYS®
July 28, 2023
Reata's Acquisition to Propel Biogen's Growth Strategy Biogen Inc. (NASDAQ: BIIB) and Reata Pharmaceuticals, Inc. (NASDAQ: RETA) have announced a
Via
Spotlight Growth
RETA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Reata Pharmaceuticals, Inc. Is Fair to Shareholders
July 28, 2023
From
Halper Sadeh LLC
Via
Business Wire
Biogen to Acquire Reata Pharmaceuticals
July 28, 2023
From
Biogen Inc.
Via
GlobeNewswire
Reata Pharmaceuticals Announces Approval of Prior Approval Supplement for SKYCLARYS® (Omaveloxolone) and Commercial Availability of SKYCLARYS for Patients with Friedreich’s Ataxia
June 27, 2023
From
Reata Pharmaceuticals, Inc.
Via
Business Wire
Bragar Eagel & Squire, P.C. Is Investigating Reata, DLocal, Comerica, and Advance Auto Parts and Encourages Investors to Contact the Firm
June 19, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Reata Pharmaceuticals Announces FDA Filing Acceptance of SKYCLARYS® (Omaveloxlone) NDA Prior Approval Supplement
June 15, 2023
From
Reata Pharmaceuticals, Inc.
Via
Business Wire
Reata Pharmaceuticals Appoints Rajiv Patni, M.D., as Executive Vice President, Chief Research & Development Officer
June 13, 2023
From
Reata Pharmaceuticals, Inc.
Via
Business Wire
Bragar Eagel & Squire, P.C. Is Investigating Reata, Comerica, and DZS and Encourages Investors to Contact the Firm
June 09, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
NASDAQ:RETA Investor Alert: Investigation over Possible Securities Laws Violations by Reata Pharmaceuticals, Inc.
June 07, 2023
San Diego, CA -- (SBWIRE) -- 06/07/2023 -- Reata Pharmaceuticals, Inc. is under investigation over potential securities laws violations in connection with certain financial statements.
Via
SBWire
Reata Pharmaceuticals Announces Participation in the Goldman Sachs 44th Annual Global Healthcare Conference
June 06, 2023
From
Reata Pharmaceuticals, Inc.
Via
Business Wire
Bragar Eagel & Squire, P.C. Is Investigating Phathom, Reata, and Comerica and Encourages Investors to Contact the Firm
June 04, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
REATA ALERT: Bragar Eagel & Squire, P.C. is Investigating Reata Pharmaceuticals, Inc. on Behalf of Reata Stockholders and Encourages Investors to Contact the Firm
May 26, 2023
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
Reata Pharmaceuticals, Inc. Announces First Quarter 2023 Financial Results and Provides an Update on Operational Progress and Clinical Development Programs
May 10, 2023
From
Reata Pharmaceuticals, Inc.
Via
Business Wire
Reata Pharmaceuticals, Inc. to Report First Quarter 2023 Financial Results and to Provide an Update on Operational Progress and Clinical Development Programs on May 10, 2023
May 02, 2023
From
Reata Pharmaceuticals, Inc.
Via
Business Wire
REATA PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Reata Pharmaceuticals, Inc. - RETA
March 31, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
The Stock That Tripled in a Day...And May Not Be Done
March 07, 2023
Reata Pharmaceuticals now has a long-coveted commercialized drug in its portfolio. Should investors covet this biotech stock for their portfolios?
Via
MarketBeat
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.